Jump To Jump To Watch View Summit Archive Biomarkers and Personalized Medicine April 8, 2022 Dr. Daniel Spratt discusses the latest developments in biomarkers. Early detection of prostate cancer is largely carried out using assessment of prostate-specific antigen (PSA) level; yet it cannot reliably discriminate between benign pathologies and clinically significant forms of prostate cancer. To overcome the current limitations of PSA, new urinary and serum biomarkers have been developed in recent years.This session was part of our VIRTUAL ZERO Prostate Cancer Summit, which took place from March 4 to 8, 2022.Watch Summit Session Archives View Summit Archive Early Detection Genetic Testing Genomic Testing Screening & PSA Test Testing & Diagnosis Videos & Webinars ZERO Prostate Cancer Summit View All Contributor Daniel Spratt, MD, Chair Department of Radiation Oncology Dr. Daniel Spratt is the Chairman and Professor of Radiation Oncology at University Hospitals (UH) Seidman Cancer Center and Case Western Reserve University (CWRU). He obtained his medical degree from Vanderbilt Medical School and completed his radiation oncology residency at Memorial Sloan Kettering Cancer Center. More for you
Dr. Daniel Spratt discusses the latest developments in biomarkers. Early detection of prostate cancer is largely carried out using assessment of prostate-specific antigen (PSA) level; yet it cannot reliably discriminate between benign pathologies and clinically significant forms of prostate cancer. To overcome the current limitations of PSA, new urinary and serum biomarkers have been developed in recent years.This session was part of our VIRTUAL ZERO Prostate Cancer Summit, which took place from March 4 to 8, 2022.Watch
Early Detection Genetic Testing Genomic Testing Screening & PSA Test Testing & Diagnosis Videos & Webinars ZERO Prostate Cancer Summit View All
Complete the Survey
